March 1, 2008Expert Review of Molecular Diagnostics

KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?

View Full Paper

Ask AI

Bookmark

Population

Experimental models including in vitro cancer cells, in vivo cancer models, experimental autoimmune…

Design

Review

Authors

CCChuan-Chu Chou CLCharles A. LunnDrew University NMNicholas MurgoloMerck & Co., Inc., Rahway, NJ, USA (United States)

Discussion

Member takes

Implication

KCa3.1 blockade merits further preclinical study in cardiovascular inflammation; leaves open clinical translation from experimental models.

Structured PICO

Population

Experimental models including in vitro cancer cells, in vivo cancer models, experimental autoimmune encephalomyelitis, and cardiovascular disease models

Intervention

KCa3.1 blockers (clotrimazole, TRAM-34, ICA-17043)

KCa3.1 blockers show potential as therapeutic agents for cancer, autoimmune disorders, and inflammatory cardiovascular diseases in experimental models.

Cite This Study

Chou et al. (2008) studied this question.

synapsesocial.com/papers/6a8874cfecbb6f2effa53f5a https://doi.org/10.1586/14737159.8.2.179

View Full Paper

Ask AI

Bookmark

Implication

KCa3.1 blockade merits further preclinical study in cardiovascular inflammation; leaves open clinical translation from experimental models.

KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?

Discussion

Member takes

Implication

Structured PICO

Cite This Study

KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider